Meningitis caused by Pseudallescheria boydii is an uncommon infection of the CNS that usually has a poor prognosis and a difficult treatment. We describe a case of chronic meningitis caused by P. boydii in an immunocompetent host that was successfully treated with voriconazole, a new antifungal agent.
Pseudallescheria boydii (asexual form, Scedosporium apiospermum) is a saprophytic fungus frequently isolated from soil and water. Infection of the central nervous system is very uncommon and it is usually associated with immunosuppression, trauma, near drowning, cerebrospinal fluid (CSF) drainage devices, and rachianesthesia. The prognosis is poor (the mortality rate is 175%). Treatment is difficult because of the resistance of the organism to many antifungal agents [1] . We describe a case of chronic meningitis caused by P. boydii that responded well to voriconazole therapy. Based on our search of MED-LINE for the period 1996-1999, we believe this is the first report of the use of voriconazole to treat a case of P. boydii meningitis.
A 24-year-old man with a normal medical history underwent excision of a pilonidal sinus cyst of the sacrum under rachianesthesia 7 months before admission; there was prolonged healing. One month later, the patient complained of headache and back pain. The CSF showed hypercellularity, an elevated protein level, and a low glucose level. Culture of the CSF was negative. The patient was treated empirically with ceftriaxone and vancomycin. After an initial improvement in his condition, fever appeared again and he was transferred to our hospital.
Upon examination, he was febrile and had papilledema, a stiff neck, 6th nerve paralysis, diminished patellar reflexes, and both ankle jerks were absent; a bilateral Lasegue's sign was present. His erythrocyte sedimentation rate was 56 mm, and his WBC count was 11,600 cells/mL. Evaluation of a CSF specimen showed a WBC count of 6400 cells/mL (56% neutrophils), a protein level of 496 mg/dL, and a glucose level of 52 mg/dL, with no microbiological growth. A cranial CT was normal. A spinal MRI showed lumbosacral arachnoiditis. A new course of antibiotic therapy with dexamethasone was initiated.
Twenty days later the patient's condition deteriorated. Evaluation of CSF from a new lumbar puncture revealed purulent liquid and a tangle of septate hyphae that were identified on culture as Scedosporium apiospermum. We initiated treatment with voriconazole (Pfizer Central Research, Sandwich, UK) on a compassionate-use basis because we could not obtain an iv formulation of miconazole. Intravenous voriconazole was ad-ministered at a dosage of 6 mg/kg/12 h for the first day, then at a dosage of 4 mg/kg/12 h. The patient became apyretic and showed clinical improvement. After 12 days the CSF became sterile. After 4 weeks, treatment was switched to oral voriconazole (200 mg/12 h). No adverse effects were observed, except for a mild and transitory increase of the hepatic enzymes.
We had the in vitro activities of various antifungal drugs examined at the National Center of Microbiology (Madrid, Spain) using a test based on the recommendations of the National Committee for Clinical Laboratory Standards. The following MICs were obtained: amphotericin B, 2 mg/mL; itraconazole, 2 mg/mL; fluconazole, 64 mg/mL; miconazole, 0.12 mg/mL; and voriconazole, 0.5 mg/mL. During oral treatment, voriconazole plasma and CSF levels were 1.92 mg/mL and 0.56 mg/mL, respectively, which exceeded the MICs. After 7 months, CSF evaluation was normal. Treatment was maintained for 12 months. Presently, the patient remains asymptomatic except for mild sciatica.
Meningitis due to P. boydii is very uncommon and is usually associated with immunosuppression or near-drowning. It normally follows an acute and fatal course and coexists with cerebral infarcts and/or abscesses [1] . Chronic presentation is rarer, usually appearing in immunocompetent individuals, although its prognosis does not change [2, 3] . In our patient, there were 2 factors that have been associated with CNS infection due to P. boydii: the rachianesthesia and the presence of a wound near the CNS [1, 2] . The characteristics of the patient's CSF were similar to those of previous cases [1] [2] [3] .
Treatment of such infections is complicated by resistance of the organism to amphotericin B and the fact that other antifungal agents penetrate poorly across the blood-brain barrier. Until now, elective treatment consisted of iv and intrathecal miconazole and surgical excision whenever possible [1, 3] . Voriconazole is a new triazole derivative that has proved to be effective against opportunistic human mycoses. To date, only 
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